Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for July 2007
July 2, 2007
- ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
- Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
- Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
- Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
- Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
- Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
- DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
- Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
- Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
- Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
- Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
- Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
- Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
- Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
- ENDEAVOR IV Clinical Trial Meets Primary Endpoint
- Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
- Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
July 3, 2007
- Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
- Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
- Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
- EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
- Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
- From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
- Researchers Discover Method for Identifying How Cancer Evades the Immune System
- Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
- Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
- Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
- Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
- Tercica to Present at Investment Conferences
July 5, 2007
- Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
- Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
- Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
- Avexa's Apricitabine Clinical Trial Update
- Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
- Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
- Genzyme Announces Results of Clinical Trial of Hylastan
- Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
- GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
- Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
- Stanford Researchers Find Brain Pathway of Depression in Rats
- NIEHS Researchers Identify Enzyme Critical in DNA Replication
- Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
July 6, 2007
- Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
- TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
- New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
- DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
- New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
- SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
- BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
- Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
- Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
- Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
- ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
July 9, 2007
- Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
- Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
- TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
- Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
- Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
- MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
- Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
- Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
- Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
- New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
- Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
- NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
- Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
- AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
- YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
- International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
- Aptuit Introduces Aptuit IVRS powered by Clarix, a Fully Web-Integrated Interactive Voice Response System Providing Customers with Easy Access to Real-Time Data
- Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell
July 10, 2007
- CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
- Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
- Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
- Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
- Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
- Protox Announces Positive Clinical Data from Prostate Cancer Study
- Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
- AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
- Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease
- BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
- Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings
- Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
July 11, 2007
- Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
- YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
- Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
- Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
- BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
- Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
- Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
- New Information on the Potential of Plasmin Shared at ISTH Congress
- Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections
- Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
- Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
- Sygnis Pharma AG announces date for presentation of clinical results
- Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
- Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results
- Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
- Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
July 12, 2007
- Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
- LAB International Announces Positive Results from its Growth Hormone Releasing Hormone (GHRH) Phase II Trial
- ISI Announces Regional eCTD Readiness Workshops for Electronic Submissions
- Progenics Selected to Present Clinical Results for Novel HIV Therapy PRO 140 at International Aids Conference
- CardioVascular BioTherapeutics Completes Pre-clinical Stroke Research
- Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
- Stem Cell Clinic Publishes First Peer Reviewed Paper on Autism Stem Cell Therapy
- Carrington Subsidiary DelSite Demonstrates Usefulness of GelSite Polymer for Therapeutic Delivery of Proteins and Peptides at Controlled Release Society Meeting
- City of Hope Selects TrialMaster to support clinical trials
- Octagon Research Solutions Limited is Granted SME Status in EU
- Acusphere Presents at Controlled Release Society
- Celsion Reports Early Success with Second Drug
- Bayer HealthCare Reports Positive Preclinical Study Results on Longer-Acting Recombinant Factor VIII Molecules
- Karo Bio Half Year Report January - June 2007
July 13, 2007
July 16, 2007
- Hollis-Eden Pharmaceuticals Reports Initial Results in Phase I Clinical Trial of HE3286 as New Type II Diabetes Treatment
- CardioVascular BioTherapeutics to Provide Clinical Trial Details on July 19 Conference Call
- Arpida Reports Positive Results of Second Pivotal Phase Iii Trial with Intravenous Iclaprim in CSSSI
- Drug Delivery Company Acrux Announces the Results of Its Phase 2 Male Testosterone Replacement Lotion Trial
- Pharsight Releases Drug Model Explorer Version 1.6
- Can-Fite Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101
- BioLineRx Announces Results of Clinical Receptor-Occupancy Study of BL-1020, a First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia
- IBM Signs $1.4 Billion Global Strategic Outsourcing Agreement With AstraZeneca
- Vernalis Reports Positive Outcome of a Phase IIA Trial of V3381 In Diabetic Neuropathic Pain
- Study Finds COPD Patients Taking Inhaled Steroids are at Greater Risk for Severe Pneumonia
- Long-Sought Adaptive Trial Predictability Announced: Cytel Inc., Tourtellotte Solutions Reveal Integrated Simulators
- Data Supports Potential Mechanism for Gentium's Defibrotide in Cancer, Diabetic Nephropathy and Veno-Occlusive Disease
- Amira Pharmaceuticals Announces Positive Initial Data From a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease
- New Clinical Results Increase Market Potential of Cytotect
July 17, 2007
- Elixir Pharmaceuticals Announces Presentation of Data in Programs to Treat and Prevent Metabolic Diseases
- Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Rheumatoid Arthritis Models
- Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir
- CVBT Announces Positive Pre-Clinical Results for Protein-Based Drug Candidate to Treat Osteoporosis
- Secondary Endpoints of Phase II/III Study Confirm Clear Benefits from Treatment With removab(R) for Patients with Malignant Ascites
- AVI BioPharma Announces Positive Pre-Clinical Study Results Presented at the 26th Annual Meeting of the American Society for Virology
- Idera Pharmaceuticals Announces Publication of Study of Toll-Like Receptor 9 Agonist in Combination with Avastin(R) in Preclinical Colon Cancer Model
- Nymox Announces New Drug Data to Be Presented at Upcoming U.S. Urology Meeting
- Nextrials Selected by AlwaysOn as an AO 100 Top Private Company Award Winner
- Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007
July 18, 2007
- Nymox Announces New Drug Data to Be Presented at Upcoming U.S. Urology Meeting
- BioSante Pharmaceuticals Announces New Findings For Potential Bird Flu Vaccine
- PPD Completes First-in-Human Trial for Novel Statin
- Anecortave Acetate Clinical Trial Data for Glaucoma Presented at World Congress of Glaucoma
- Purdue Pharma Turns to Microsoft for Document Management Solution
- TechnoVax Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate
- BlueCielo ECM Solutions Releases InnoCielo View 2008
- Definiens Reveals an Integrated Data Management Approach For Image Analysis in Life Sciences Enterprises
July 19, 2007
- ImmuneRegen BioSciences, Inc. and Virion Systems, Inc. Continue Testing Viprovex and Tamiflu as Possible Influenza Co-Treatment
- Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint
- Landmark Cimzia Data in Crohn's Disease Published in New England Journal of Medicine
- Positive Preliminary Results of Phase IIb AK Study
- Pivotal Cimzia Data in Crohn's Disease Published in New England Journal of Medicine
July 20, 2007
- Journal of Clinical Oncology Publishes Data on Zolinza (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
- Wyeth and Progenics Announce Positive Preliminary Results of Phase 1 Study of New Oral Formulation of Methylnaltrexone
- Sorel Forge Selects Amadeus eQCM Software Solution
- GlycoMimetics, Inc. Highlights Advances in Lead Drug Candidate for Sickle Cell Patients at International Glycobiology Conference
- Samaritan Announces Positive Preliminary Results in a Phase IIb Study For Its Novel Oral HIV Entry Inhibitor
- Improvement Following ADHD Treatment Sustained in Most Children, But Linked Problems Persist Into Adolescence -- Major Follow-up Study
- New Data Show Tekturna and Diovan Used Together Provide Additive Blood Pressure Reductions
- Pharsight Releases Drug Model Explorer Version 1.6
July 23, 2007
- Advanced Magnetics Announces Positive Results from Fourth Phase III Study of Ferumoxytol as an Intravenous Iron Replacement Therapeutic in Chronic Kidney Disease Patients
- ANX-201 Combination Therapy Demonstrates Synergistic Inhibition of HIV-1 in Preclinical Tests
- Nventa Announces Publication of Final Results of a Phase 2 Study of HspE7 in Cervical Dysplasia
- Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease
- Pluristem's PLX Cells Show Promise in Treating Limb Ischemia
- Paper in Cancer Biology & Therapy Confirms In Vitro Cytotoxic Effect of Alfacell's Onconase
- New Interim Results Demonstrate High Response Rate With Fuzeon Plus Darunavir Regardless of Existing Protease Inhibitor Resistance
- 144-Week Data from Gilead's Study 934 Comparing Truvada to Combivir Both in Combination with Sustiva Presented At International AIDS Society Meeting in Sydney
- MedImmune Announces Interim Phase 1 Study Results for Potential Asthma Therapy
- Sygnis Announces Successful Completion of the Clinical IIa Study for AX200 in Stroke
- New Data Suggest Boosted Invirase Has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks
- Baxter Announces Preliminary Phase I/II Data for Seasonal Influenza Vaccine Candidate
- SYGNIS successfully completes clinical study IIa for AX200 in stroke (AXIS)
July 24, 2007
- Isentress (raltegravir), an Investigational Oral HIV Integrase Inhibitor, in Combination Therapy Demonstrated HIV RNA Reduction Comparable to Efavirenz in Treatment-Naive HIV-Positive Patients
- Etrials EDC to Interface with Green Mountain Logic Labpas CT
- Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients
- Vicriviroc Demonstrates Potent Viral Suppression Through 48 Weeks of Therapy in ACTG Phase II Study in Treatment-Experienced HIV Patients
- Starpharma Presents Positive Results of Clinical Study of VivaGel in Men at 4th International AIDS Society Conference
- Orexigen Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of Empatic to Treat Obesity
- Protalex Announces Preliminary Results in Phase I Clinical Trial
- Phase Forward and Sentrx Partner to Offer Integrated Drug Safety Services
- OrexigenReports Top-line 24 Week Results for Ph IIb EMPATIC? Obesity Trial
- Faster-Acting Antidepressants Closer to Becoming a Reality
July 25, 2007
- New Head-to-Head Study Comparing Lexiva and Atazanavir Show Similar Efficacy and Lipid Changes
- Analysis of Ushercell HIV Trials Reveals Difference in Seroconversion Groups Not Statistically Significant
- BioSante Pharmaceuticals Announces Positive Resultsfor its CaP Technology for Use in Aesthetic Medicine
- BioSante Pharmaceuticals Announces Positive Results for its CaP Technology for Use in Aesthetic Medicine
- Targacept Presents Data from Tridmac Trial Showing Positive Effects of Mecamylamine as Augmentation Treatment for Depressed Patients
- Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritis
- Animal Studies Show Promising Therapeutic Dosing Results Using an Antisense Agent to Treat Heart Disease
- Panacos Announces Five Presentations on its Antiviral Programs at International AIDS Society Conference
- AVI BioPharma Partner Global Therapeutics Announces Positive Pre-Clinical Results Shown Using Neugene Antisense Drug in Prevention of Cardiovascular Restenosis
- The Journal of Hand Surgery Publishes Initial Phase III Data on Xiaflextm (formerly known as AA4500), Auxilium's Investigational Treatment for Patients with Dupuytren's Contracture
- Fourth Actemra (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
- Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting
- Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
- Treating HIV-Infected Infants Early Helps Them Live Longer
- CytoDyn Study of Bird Flu Vaccines Illustrates Subsidiary's Unique Opportunity
- Delphian Pharma Announces-Discovery of Novel Anti-tumor Antimitotic Agents That Also Reverse Tumor Resistance
July 26, 2007
- Anti-Tumor Activity and Pharmacokinetic Properties of NKTR-102 (PEG-irinotecan) to be Presented at Upcoming Oncology Meeting
- First Peer-Reviewed Preclinical and Early Phase 1 Results for NKTR-118 (oral PEG-naloxol) to be Presented at Upcoming Pharmacology and Pain Management Meetings
- Ubisol-Aqua: Coenzyme Q10 May Prevent Toxicity of HIV Drug Therapy
- OctoPlus Announces Promising Results for Locteron Phase IIa Clinical Study
- Avexa Releases ATC Phase IIb Clinical Trial Update
- Controversy Over Use of Antipsychotic Drugs for Dementia, From the Harvard Mental Health Letter
- OctoPlus announces promising results for Locteron Phase IIa clinical study
- Yale School of Medicine Shows First Detailed View of Molecular Structure May Usher in New Class of Cancer Drugs
July 27, 2007
- Genaera Corporation Presents New Preclinical Data for Obesity Compound Trodusquemine (MSI-1436) at CBI Conference
- Gene Logic Drug Candidate Shows Positive In Vivo Test Results
- Positive Aggrastat Results Versus Integrilinr Featured in American Heart Journal
July 30, 2007
- Intellect Neurosciences, Inc. Announces the Release of Audited Data for its Drug Candidate, Oxigon, From a Single Dose Phase I Trial
- Study Discovers Link Between Increased White Matter in the Brain and Poor Motor Skills in Children With Autism
- Can-Fite: Pre-clinical Studies Demonstrate that the Excipients Used in the Placebo and CF101 Drug Enhanced the Anti-inflammatory Effect of Methotrexate (MTX)
- Investigational Anti-Inflammatory Drug Produces Promising Results in Animal Studies
- ClinPhone and LabPas CT Agree to Interface
- AlphaVax Announces Interim Results From Phase 1 Influenza Vaccine Clinical Trial
July 31, 2007
- Infringement Claims Against DATATRAK Dismissed
- Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Eye Disorders
- OncoGenex and Isis Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans
- New Study Finds Tindamax to be Effective, Well-Tolerated Treatment for Bacterial Vaginosis
- Phase Forward Signs Multi-Year Enterprise Agreement with ICON
- Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim
- The International Journal of Cancer Publishes Studies on Generex Biotechnology's Anti-cancer Activity of Its Immunotherapeutic Vaccine
- OncoGenex and Isis Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans
- Almac Clinical Technologies Launches IXR Express: A new way for clients to accelerate the clinical trial process
